Search

Your search keyword '"Zandong Yang"' showing total 4 results
Start Over Author "Zandong Yang" Publisher american society of clinical oncology (asco)
4 results on '"Zandong Yang"'

1. Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial)

Author

Julio Antonio Peguero, Richy Agajanian, Zandong Yang, Patrick Wayne Cobb, Inderjit Mehmi, Osama Hlalah, Alvaro Restrepo, Lee S. Schwartzberg, Jayaram S. Bharadwaj, and Gajanan Bhat

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Myelosuppressive Chemotherapy, business.industry, law.invention, Human immunoglobulin, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, 030212 general & internal medicine, business, Pegfilgrastim, medicine.drug, Severe neutropenia
Abstract

e12513Background: Eflapegrastim is a novel investigational biologic comprised of recombinant human G-CSF covalently linked to the human immunoglobulin G4FC fragment using proprietary LAPSCOVERY™ te...

Published
2018
Full Text
View/download PDF

2. A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer

Author

Guru Reddy, Zandong Yang, Mark A. Socinski, David Chu, Nishan Tchekmedyian, and Gajanan Bhat

Subjects
0301 basic medicine, Cancer Research, business.industry, Poziotinib, Phases of clinical research, medicine.disease, 03 medical and health sciences, chemistry.chemical_compound, Exon, 030104 developmental biology, 0302 clinical medicine, Oncology, chemistry, 030220 oncology & carcinogenesis, Mutation (genetic algorithm), Quinazoline, Cancer research, Medicine, In patient, Receptor, business, Lung cancer
Abstract

TPS9106Background: Poziotinib is a novel, oral, quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through the EGFR family of tyrosine-kinase receptors, including human epiderma...

Published
2018
Full Text
View/download PDF

3. Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy

Author

David B. Weiner, Jessica Goldenberg, Corey J. Langer, Christine Loch, Zandong Yang, Jian Yan, Angela DeMichele, Jessica Lee, Mark L. Bagarazzi, Charu Aggarwal, Matthew P. Morrow, Robert H. Vonderheide, David L. Bajor, and Peter J. O'Dwyer

Subjects
Cancer Research, Telomerase, business.industry, cells, Protein subunit, Electroporation, medicine.medical_treatment, Immunotherapy, Reverse transcriptase, enzymes and coenzymes (carbohydrates), Oncology, embryonic structures, Immunology, Interleukin 12, medicine, Cancer research, Adjuvant therapy, Telomerase reverse transcriptase, biological phenomena, cell phenomena, and immunity, business, neoplasms
Abstract

TPS3104 Background: hTERT, the human catalytic reverse transcriptase subunit of telomerase, is highly expressed in breast, lung, and pancreatic cancers. Peptides derived from hTERT can be recognize...

Published
2015
Full Text
View/download PDF

4. Effect of abiraterone acetate and low-dose prednisone on PSA in patients with nonmetastatic castration-resistant prostate cancer: The results from IMAAGEN core study

Author

Charles J. Ryan, Neal D. Shore, Jannell DePalantino, Philip W. Kantoff, J. Wang, Zandong Yang, Tracy McGowan, E. David Crawford, Willie Underwood, and Anil Londhe

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Low dose, Abiraterone acetate, Urology, Prodrug, Castration resistant, medicine.disease, chemistry.chemical_compound, Prostate cancer, Endocrinology, Oncology, chemistry, Prednisone, Internal medicine, medicine, In patient, business, Testosterone, medicine.drug
Abstract

5086 Background: Abiraterone acetate (AA) is a prodrug of abiraterone, which is a selective, irreversible CYP17 inhibitor of androgen biosynthesis and significantly reduces testosterone production ...

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results